MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Stock-based compensation
Prepaid expenses
Non-cash lease expense
Negative Cash Flow Breakdown
Accounts payable and other curre...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-613,933
-686,425
-1,295,365
-712,184
Stock-based compensation
33,000
-
0
0
Non-cash lease expense
2
159
237
238
Prepaid expense and other assets
-
-
-16,288
-
Prepaid expenses
-13,927
13,835
-
-4,597
Accounts payable and other current liabilities
-208,216
-384,781
678,042
-53,896
Net cash flows from operating activities
-775,220
-1,084,515
-601,165
-761,245
Net change in cash and cash equivalents
-775,220
-1,084,515
-601,165
-761,245
Cash and cash equivalents at beginning of period
1,290,978
2,375,493
2,976,658
5,606,863
Cash and cash equivalents at end of period
515,758
1,290,978
2,375,493
2,976,658
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net change in cash
and cash...
-$775,220
(58.52%↑ Y/Y)
Stock-based compensation
$33,000
(41.12%↑ Y/Y)
Prepaid expenses
-$13,927
(-429.24%↓ Y/Y)
Non-cash lease expense
$2
(-99.37%↓ Y/Y)
Net cash flows from
operating activities
-$775,220
(58.52%↑ Y/Y)
Canceled cashflow
$46,929
Net loss
-$613,933
(52.51%↑ Y/Y)
Accounts payable and
other current...
-$208,216
(65.04%↑ Y/Y)
Buy us a coffee
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)